Advertisement

Topics

Alnylam Pharmaceuticals, Inc. and The Medicines Company Company Profile

17:36 EDT 24th September 2018 | BioPortfolio


News Articles [1367 Associated News Articles listed on BioPortfolio]

Alnylam Pharma Reports PRIME Designation For Lumasiran

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran, a...

Alnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Need...

Patisiran a launching pad for Alnylam venture into NASH research

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals will collaborate to identify RNAi therapeutics…

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following confere...

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing tec...

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following confere...

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following confere...

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to...

Drugs and Medications [1702 Associated Drugs and Medications listed on BioPortfolio]

Cimetidine [Walgreen Company]

Walgreen Co. Cimetidine 200 Drug Facts

Qsr hand sanitizer [Kay Chemical Company]

Drug Facts

Terbinafine hydrochloride [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use terbinafine hydrochloride safely and effectively. See full prescribing information for terbinafine hydrochloride tablets.Terbinafine H...

Conquest [KAY CHEMICAL CO.]

Drug Facts

Sudogest [H.J. Harkins Company, Inc.]

SudoGestNasal Decongestant

PubMed Articles [411 Associated PubMed Articles listed on BioPortfolio]

What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.

The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the European Medicines Agency (EMA) have a long-standing experience of reviews of new medicines, and they meet their target pre-marke...

Alnylam launches era of RNAi drugs.

Health-industry linkages for local health: reframing policies for African health system strengthening.

The benefits of local production of pharmaceuticals in Africa for local access to medicines and to effective treatment remain contested. There is scepticism among health systems experts internationall...

Does consumer medicines interest reflect medicines use? An Australian observational study comparing medicines call center queries with medicines use.

Consumers have questions about their medication but the nature of these concerns and how they reflect medication use is unknown.

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

Clinical Trials [725 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Buspirone Hydrochloride 30mg Tablets, Fasting

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BU...

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study

To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt. Ltd., India and SOLODYN® (minocycline h...

Companies [3244 Associated Companies listed on BioPortfolio]

Alnylam Pharmaceuticals, Inc. and The Medicines Company

The Medicines Company and Alnylam Pharmaceuticals, Inc.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The C...

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Ligand Pharmaceuticals Incorporated and The Medicines Company

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise m...

More Information about "Alnylam Pharmaceuticals, Inc. and The Medicines Company" on BioPortfolio

We have published hundreds of Alnylam Pharmaceuticals, Inc. and The Medicines Company news stories on BioPortfolio along with dozens of Alnylam Pharmaceuticals, Inc. and The Medicines Company Clinical Trials and PubMed Articles about Alnylam Pharmaceuticals, Inc. and The Medicines Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Pharmaceuticals, Inc. and The Medicines Company Companies in our database. You can also find out about relevant Alnylam Pharmaceuticals, Inc. and The Medicines Company Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record